Arecor Therapeutics (AREC LN)

Arecor Therapeutics PLC is a clinical-stage biopharmaceutical company focused on developing superior therapeutics to address unmet patient needs in diabetes, obesity, and other cardiometabolic diseases. The company utilizes its proprietary Arestat® formulation technology platform to create enhanced reformulations of therapeutic products and to develop a portfolio of proprietary products, including AT278, an ultra-rapid acting insulin. Arecor Therapeutics plc was founded in 2007 and is headquartered in Little Chesterford, United Kingdom.